Literature DB >> 11956979

Complications associated with bone cementing for the treatment of giant cell tumors of bone.

Takuro Wada1, Mitsunori Kaya, Satoshi Nagoya, Satoshi Kawaguchi, Kazuo Isu, Toshihiko Yamashita, Shinya Yamawaki, Seiichi Ishii.   

Abstract

Aretrospective review was conducted of giant cell tumors treated between 1984 and 1998 using the technique of aggressive curettage through a large bone window followed by acrylic cement reconstruction. Fifteen patients with a mean follow-up time of 46 months (range, 24-188 months) were identified. One patient had a local recurrence 24 months postoperatively. All the patients showed a radiolucent zone at the bone-cement interface up to 2.5 mm in width during the first 6 months after operation. However, the radiolucent zones were nonprogressive and did not affect the stability of the bone cement. Osteoarthritis of the knee joint occurred 14 years postoperatively in one patient with an intraarticular fracture at presentation. A stress fracture occurred in one patient who had the largest tumor in the distal femur. Acrylic cement reconstruction is a safe and effective procedure that provides local adjuvant therapy. Giant cell tumors with an associated intraarticular fracture remain a challenging problem to treat.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11956979     DOI: 10.1007/s007760200033

Source DB:  PubMed          Journal:  J Orthop Sci        ISSN: 0949-2658            Impact factor:   1.601


  23 in total

1.  [Conductive bone substitute material with variable antibiotic delivery].

Authors:  C Englert; P Angele; J Fierlbeck; S Dendorfer; T Schubert; R Müller; S Lienhard; J Zellner; M Nerlich; C Neumann
Journal:  Unfallchirurg       Date:  2007-05       Impact factor: 1.000

2.  The Most Appropriate Reconstruction Method Following Giant Cell Tumor Curettage: A Biomechanical Approach.

Authors:  Azadeh Ghouchani; Mohammad H Ebrahimzadeh; Gholamreza Rouhi
Journal:  Arch Bone Jt Surg       Date:  2018-03

3.  Ethanol as a local adjuvant for giant cell tumor of bone.

Authors:  Kevin B Jones; Barry R DeYoung; Jose A Morcuende; Joseph A Buckwalter
Journal:  Iowa Orthop J       Date:  2006

Review 4.  The clinical approach toward giant cell tumor of bone.

Authors:  Lizz van der Heijden; P D Sander Dijkstra; Michiel A J van de Sande; Judith R Kroep; Remi A Nout; Carla S P van Rijswijk; Judith V M G Bovée; Pancras C W Hogendoorn; Hans Gelderblom
Journal:  Oncologist       Date:  2014-04-09

Review 5.  The impact of curettage technique on local control in giant cell tumour of bone.

Authors:  Gennady N Machak; Andrey I Snetkov
Journal:  Int Orthop       Date:  2020-10-22       Impact factor: 3.075

6.  Supplemental Bone Grafting in Giant Cell Tumor of the Extremity Reduces Nononcologic Complications.

Authors:  Joseph Benevenia; Steven M Rivero; Jeffrey Moore; Joseph A Ippolito; Daniel A Siegerman; Kathleen S Beebe; Francis R Patterson
Journal:  Clin Orthop Relat Res       Date:  2017-03       Impact factor: 4.176

7.  Giant cell tumor of bone: treatment and outcome of 214 cases.

Authors:  Maurice Balke; Laura Schremper; Carsten Gebert; Helmut Ahrens; Arne Streitbuerger; Gabriele Koehler; Jendrik Hardes; Georg Gosheger
Journal:  J Cancer Res Clin Oncol       Date:  2008-03-06       Impact factor: 4.553

8.  The Successful Management of a Repetitively Infected Recurrent Proximal Humerus Giant Cell Tumour of 20 Years' Duration With Two-Staged Surgery: A Rare Case Report.

Authors:  Alok C Agrawal; Ranjeet Choudhary; Shilp Verma
Journal:  Cureus       Date:  2021-04-14

9.  Curettage of benign bone tumors without grafts gives sufficient bone strength.

Authors:  Takashi Yanagawa; Hideomi Watanabe; Tetsuya Shinozaki; Kenji Takagishi
Journal:  Acta Orthop       Date:  2009-02       Impact factor: 3.717

10.  p63 as a prognostic marker for giant cell tumor of bone.

Authors:  Michiro Yanagisawa; Hiroshi Kakizaki; Kyoji Okada; Tomoaki Torigoe; Tomomi Kusumi
Journal:  Ups J Med Sci       Date:  2012-10-04       Impact factor: 2.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.